These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29540190)

  • 1. Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study.
    Okihiro A; Hasija R; Fung L; Cameron B; Feldman BM; Laxer R; Schneider R; Silverman E; Spiegel L; Yeung RSM; Tse SML
    Pediatr Rheumatol Online J; 2018 Mar; 16(1):17. PubMed ID: 29540190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.
    Wendling D; Paccou J; Berthelot JM; Flipo RM; Guillaume-Czitrom S; Prati C; Dernis E; Direz G; Ferrazzi V; Ristori JM;
    Semin Arthritis Rheum; 2011 Dec; 41(3):503-10. PubMed ID: 21862108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.
    Horneff G; Klein A; Oommen PT; Hospach A; Foeldvari I; Feddersen I; Minden K
    Clin Exp Rheumatol; 2016; 34(6):1113-1120. PubMed ID: 27749226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.
    Pastore S; Naviglio S; Canuto A; Lepore L; Martelossi S; Ventura A; Taddio A
    Paediatr Drugs; 2018 Apr; 20(2):165-171. PubMed ID: 29214394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
    Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F; Niccoli L; Goletti D
    J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
    Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
    J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB; Furst DE
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
    Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
    Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
    Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E
    Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
    Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
    J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
    Perez-Alvarez R; Perez-de-Lis M; Diaz-Lagares C; Pego-Reigosa JM; Retamozo S; Bove A; Brito-Zeron P; Bosch X; Ramos-Casals M
    Semin Arthritis Rheum; 2011 Oct; 41(2):256-64. PubMed ID: 21277618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.